Compare Johnson & Johnson (JNJ) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Skyworks Solutions Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Skyworks Solutions Inc trades at $76.59 (market cap $12.15B). The key difference: Johnson & Johnson is far larger — about 50.9× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Skyworks Solutions Inc for 50 Days on average.
| JNJ | SWKS | |
|---|---|---|
Market Cap | $618.09B | $12.15B |
Volume | 6,050,983 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $278.43 | $91.45 |
52-Week Low | $186.00 | $52.50 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $646.37B | $12.03B |
Dividend Yield | 2.09% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Skyworks Solutions (SWKS) trades at $76.35, down 8.49% in the last session, reflecting near-term pressure despite beating earnings estimates in recent quarters. The stock exhibits a bearish technical signal, with key support at $76, while fundamentals show declining revenue and net income margins over recent years. The pending merger with Qorvo represents a significant strategic development, aimed at enhancing scale and market diversification.
The investment outlook is mixed, with analyst consensus leaning bullish (60% buy ratings) and a price target of $78.80 offering modest upside. However, risks include execution challenges from the merger, competitive pressures in semiconductors, and ongoing profitability declines. The stock's current valuation at a P/E of 41.84 appears elevated relative to earnings growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
